Introduction {#s01}
============

Non-small cell lung cancer (NSCLC) accounts for 80% of all cases of lung cancer worldwide and in China, and most patients are staged as "unresectable", "advanced" or "metastatic" ([@b1],[@b2]). Platinum-based chemotherapy regimens have, for a long time, been the standard first-line treatment for NSCLC with no sensitizing genetic mutations ([@b3]). However, their efficacy is limited with 5-year survival of 10%−15% and median survival of approximately 8−10 months ([@b4]-[@b6]).

Vascular endothelial growth factor (VEGF) is an important mediator in tumor-associated growth and angiogenesis ([@b7]). Bevacizumab (Bev; Avastin), a recombinant humanized monoclonal antibody, has been approved as a VEGF antagonist for treatment of several cancer types ([@b8],[@b9]). Since 2004, it has been demonstrated that Bev-combined platinum-based standardized treatment can prolong progression-free survival (PFS) of patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC) who can tolerate such treatment ([@b10]-[@b12]). Based on such findings, combination of Bev with chemotherapy was approved by the USA Food and Drug Administration for first-line treatment of NS-NSCLC. Subsequently, Bev-specific observational cohort studies were initiated to define the clinical outcomes among a broader population of patients receiving Bev-containing regimens in a real-world setting. Several observational cohort studies have compared the regimen of paclitaxel/carboplatin plus Bev and paclitaxel/carboplatin therapy in advanced NSCLC, and demonstrated the significant response and survival benefits of Bev ([@b13],[@b14]). However, most available supporting data were from studies of paclitaxel/platinum in combination with Bev in Western countries, in which Bev was administered at 15 mg/kg every 3 weeks.

Compared with paclitaxel, pemetrexed-platinum chemotherapy combined with Bev at 7.5 mg/kg is used more widely in NS-NSCLC patients in China. Besides, The JMDB trial showed the noninferiority of pemetrexed/cisplatin over gemcitabine/cisplatin with regard to PFS in NSCLC patients \[4.8 *vs*. 5.1 months; hazard ratio (HR)=1.04; 95% confidence interval (95% CI), 0.94−1.15\] ([@b15]).

At present, the efficacy and safety of first-line Bev (7.5 mg/kg)-containing pemetrexed-platinum chemotherapy has not been evaluated specifically. Therefore, we conducted a retrospective propensity score-matched (PSM) real-world study in a Chinese population with advanced NS-NSCLC.

Materials and methods {#s02}
=====================

Study design and patient enrollment {#s02.01}
-----------------------------------

This retrospective, single-center study captured the clinical data from Chinese patients with advanced NS-NSCLC who received first-line paclitaxed-platinum chemotherapy with or without Bev between February 2010 and September 2017 at National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The inclusion criteria were: 1) pathological diagnosis and radiographic examination confirmed local advanced or metastatic NS-NSCLC (stage IIIB−IV); 2) confirmation of written informed consent for chemotherapy; 3) receiving first-line pemetrexed-platinum chemotherapy with or without Bev; 4) receiving ≥2 cycles of chemotherapy; and 5) completeness of full medical records. Exclusion criteria were patients: 1) with squamous lung cancer; 2) who received maintenance treatment with epidermal growth factor receptor-tyrosine kinase inhibitors; 3) who received second- or more than second-line therapy with Bev after progression of first-line chemotherapy; or 4) lost to follow-up.

The patient flowchart is presented in *[Figure 1](#Figure1){ref-type="fig"}*. The study protocol was approved by the Independent Ethics Committee at the National Cancer Center (Beijing, China).

![Flowchart showing patient selection. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PPCT, platinum-pemetrexed-based chemotherapy; Bev, bevacizumab.](cjcr-31-5-749-1){#Figure1}

Data collection {#s02.02}
---------------

Patient data (chief complaint, disease history, physical examination, imaging examinations and biochemical laboratory tests) were collected retrospectively from the electronic data system at our institute.

Treatment responses were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST1.1) ([@b16],[@b17]). Complete response (CR) was defined as the disappearance of all target lesions and reduction in the short axis of any pathological lymph nodes (target or non-target) to \<10 cm. Partial response (PR) was defined as a decrease of ≥30% in the sum of the diameters of target lesions. Progressive disease (PD) was defined as an increase of ≥20% in the sum of target lesions with an absolute increase of \>5 mm, or the appearance of any one or more new lesions. Stable disease (SD) was defined as lesions whose shrinkage was not sufficient to qualify as PR or whose increase was not sufficient to qualify as PD. The objective response rate (ORR) is calculated as CR + PR. The disease control rate (DCR) is calculated as CR + PR + SD. The endpoint of primary efficacy, PFS, was defined as the time from treatment initiation until the first sign of disease progression or death from any cause.

Toxicities were evaluated according to the National Cancer Institute---Common Toxicity Criteria for Adverse Events version 4.0.

Statistical analysis {#s02.03}
--------------------

A one-to-one PSM method ([@b18]) was applied to reduce the selection bias when dealing with the large number of covariates among patients who received Bev treatment *versus* those who did not. Each variable was multiplied by a coefficient that was calculated by the logistic regression analysis, and the sum of these values was considered to be the propensity score for individual patients.

In the present study, the variables included in PSM were age, gender, smoking status, comorbidity, baseline histology, sensitizing driven mutations, brain metastases, pleural invasion, weight loss \>5%, pemetrexed regimens, previous surgery, radiotherapy history, and history of hemoptysis. A description of categorical variables and the Chi-square test were used to check the balance between PSM subgroups.

Student's *t* tests and Mann-Whitney *U* tests were used to establish the statistical significance of continuous categorical variables in all subgroups. The Kaplan-Meier method was used to estimate the impact of the duration of Bev administration upon survival, followed by the log-rank test to determine the statistical significance. Multivariate Cox analyses were used to estimate the effect of Bev treatment on PFS before and after match. As for matched variables, the Cox regression was performed among patients before PSM to explore their potential predictive values of survivals. The research goals mentioned above were achieved by analyses with IBM SPSS Statistics (Version 22.0; IBM Corp., New York, USA).

Results {#s03}
=======

Clinical characteristics {#s03.01}
------------------------

Between February 2010 and September 2017, 750 Chinese patients with advanced NS-NSCLC were investigated initially. Finally, 415 eligible patients were enrolled according to their treatment regimens: 309 patients in the Bev(−) group and 106 in the Bev(+) group.

The median age was 58 (range, 25−78) years and the ratio of males to females was 217 to 198. An extremely high prevalence of adenocarcinoma (404, 97.3%) was observed. Patients with an Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≥2 (n=25; 6.0%), brain metastases (n=59; 14.2%), or a history of hemoptysis (n=33; 8.0%) were also included in our study. At baseline, 77 patients (18.6%) had a history of hypertension, 26 (6.3%) had diabetes mellitus, 15 (3.6%) had cardiovascular disease, 2 (0.5%) had a thrombosis disorder, and 7 (1.7%) had cerebrovascular disease. All these patients were receiving the relevant medications concomitantly. Baseline characteristics such as pleural invasion, ECOG PS, and history of surgery/radiotherapy were not distributed evenly across Bev(−) and Bev(+) groups before PSM (*[Table 1](#Table1){ref-type="table"}*).
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Baseline characteristics before propensity-score-matched stratification by regimens

  Characteristics                                                                  PPCT (n=309) \[n (%)\]   Bev+PPCT (n=106) \[n (%)\]   P
  -------------------------------------------------------------------------------- ------------------------ ---------------------------- -------
  Age ( $\documentclass[12pt]{minimal}                                             56.3±10.3                56.2±10.2                    0.989
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  　≥60 years                                                                      123 (39.8)               43 (40.6)                    0.909
  Male                                                                             168 (54.4)               49 (46.2)                    0.176
  ECOG PS                                                                                                                                0.082
  　0−1                                                                            288 (93.2)               102 (96.2)                   
  　≥2                                                                             21 (6.8)                 4 (3.8)                      
  Smoking history                                                                                                                        0.338
  　No                                                                             185 (59.9)               72 (67.9)                    
  　Yes                                                                            124 (40.1)               34 (32.1)                    
  Comorbidities                                                                                                                          0.082
  　Hypertension                                                                   61 (19.7)                16 (15.1)                    
  　Diabetes mellitus                                                              23 (7.4)                 3 (2.8)                      
  　Cardiovascular disease                                                         12 (3.9)                 3 (2.8)                      
  　Thrombotic disease                                                             1 (0.3)                  1 (0.9)                      
  　Cerebrovascular disease                                                        4 (1.3)                  3 (2.8)                      
  　Other                                                                          57 (18.4)                28 (26.4)                    
  Baseline histology                                                                                                                     0.914
  　Adenocarcinoma                                                                 301 (97.4)               103 (97.2)                   
  　Large-cell carcinoma                                                           1 (0.3)                  0 (0)                        
  　Bronchoalveolar carcinoma                                                      1 (0.3)                  0 (0)                        
  　Mixed                                                                          6 (2.0)                  3 (2.8)                      
  Sensitizing driven mutation                                                                                                            
  　EGFR positive                                                                  99 (32.0)                28 (26.4)                    0.285
  　T790M positive                                                                 6 (1.9)                  2 (1.9)                      0.668
  　ALK positive                                                                   19 (6.1)                 8 (7.5)                      0.380
  　C-MET positive                                                                 3 (0.9)                  1 (0.9)                      0.730
  　ROS-1 positive                                                                 2 (0.6)                  0 (0)                        0.554
  Pemetrexed regimens                                                              309 (100)                106 (100)                    −
  Brain metastases                                                                 46 (14.9)                13 (12.3)                    0.312
  Pleural invasion                                                                 92 (29.8)                43 (40.6)                    0.028
  Weight loss \>5%                                                                 22 (7.1)                 5 (4.7)                      0.269
  History of hemoptysis                                                            26 (8.4)                 7 (6.6)                      0.359
  Maintenance therapy                                                              132 (42.7)               68 (64.2)                    0.001
  Previous surgery                                                                 33 (10.7)                22 (20.8)                    0.008
  Radiotherapy history                                                             43 (13.9)                22 (20.8)                    0.067

Treatment {#s03.02}
---------

All enrolled patients received pemetrexed plus platinum doublets with or without Bev. Chemotherapy was administered at 3-week intervals: pemetrexed (500 mg/m^2^, i.v., on d 1), platinum \[cisplatin, 25 mg/m^2^, i.v., on d 1−3 or carboplatin (area under the curve, 4−5), i.v., on d 1\], and Bev (7.5 mg/kg, i.v., on d 1). The median number of chemotherapy cycles was five. Two-hundred patients (48.2%) received a median of four cycles of pemetrexed maintenance treatment after induction chemotherapy. Patients in the Bev(+) group received 4−6 cycles (median, 4) of Bev plus pemetrexed-platinum induction chemotherapy followed by Bev-containing pemetrexed maintenance treatment.

To reduce the risk of a selection bias, one-to-one PSM was used for the selection of the Bev(−) group (n=309) and Bev(+) group (n=106) pairs, with a caliper width of 0.15 of standard deviation. One-hundred and five patients from each group were well matched without a significant difference at baseline (*[Table 2](#Table2){ref-type="table"}*).

###### 

Baseline characteristics after propensity score-matched stratification by regimens

  Characteristics                                                                  PPCT (n=105) \[n (%)\]   Bev+PPCT (n=105) \[n (%)\]   P
  -------------------------------------------------------------------------------- ------------------------ ---------------------------- -------
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  　≥60 years                                                                      39 (37.1)                43 (41.0)                    0.336
  Male                                                                             53 (50.5)                48 (45.7)                    0.290
  ECOG PS                                                                                                                                0.169
  　0−1                                                                            94 (89.5)                101 (96.2)                   
  　≥2                                                                             11 (10.5)                4 (3.8)                      
  Smoking status                                                                                                                         0.667
  　No                                                                             71 (67.6)                72 (68.6)                    
  　Yes                                                                            34 (32.4)                33 (31.4)                    
  Comorbidities                                                                                                                          0.060
  　Hypertension                                                                   23 (21.9)                16 (15.2)                    
  　Diabetes                                                                       8 (7.6)                  3 (2.9)                      
  　Cardiovascular disease                                                         6 (5.7)                  3 (2.9)                      
  　Thrombosis disease                                                             0 (0)                    1 (1.0)                      
  　Cerebrovascular disease                                                        1 (1.0)                  3 (2.9)                      
  　Other                                                                          13 (12.4)                28 (26.7)                    
  Baseline histology                                                                                                                     0.998
  　Adenocarcinoma                                                                 102 (97.1)               102 (97.1)                   
  　Large cell carcinoma                                                           1(1.0)                   1 (1.0)                      
  　Bronchoalveolar carcinoma                                                      1 (1.0)                  1 (1.0)                      
  　Mixed                                                                          1 (1.0)                  1 (1.0)                      
  Sensitizing driven mutation                                                                                                            
  　EGFR positive                                                                  25 (23.8)                28 (26.7)                    0.512
  　T790M positive                                                                 3 (2.9)                  2 (1.9)                      0.500
  　ALK positive                                                                   9 (8.6)                  8 (7.6)                      0.500
  　C-MET positive                                                                 2 (1.9)                  1 (1.0)                      0.500
  　ROS-1 positive                                                                 0 (0)                    0 (0)                        −
  Pemetrexed regimens                                                              105 (100)                105 (100)                    −
  Brain metastases                                                                 14 (13.3)                13 (12.4)                    0.500
  Pleural invasion                                                                 43 (41.0)                42 (40.0)                    0.500
  Weight loss \>5%                                                                 8 (7.6)                  5 (4.8)                      0.284
  History of hemoptysis                                                            8 (7.6)                  7 (6.7)                      0.500
  Maintenance therapy                                                              46 (43.8)                67 (63.8)                    0.001
  Previous surgery                                                                 17 (16.2)                21(20.0)                     0.296
  Radiotherapy history                                                             18 (17.1)                22 (21.0)                    0.299

Bev administration is one of significant prognostic factors of PFS {#s03.03}
------------------------------------------------------------------

Patients in the Bev(+) group had a superior median PFS to those in the Bev(−) group (9.8*vs*. 7.8 months, P=0.006) (*[Figure 2A](#Figure2){ref-type="fig"}*) before PSM. Furthermore, the survival benefit of patients in the Bev(+) group was further confirmed after PSM (median PFS, 9.8 *vs*. 6.6 months, P\<0.001) (*[Figure 2B](#Figure2){ref-type="fig"}*). Bev-containing regimens were proven to be one of the significant beneficial prognostic factors of PFS before (HR=0.70; 95% CI, 0.55−0.90; P=0.005) and after PSM (HR=0.66; 95% CI, 0.48−0.90; P=0.010). Besides, patients receiving maintenance therapy had more favorable PFS than those who did not. Median PFS was 4.8, 8.6 and 12.3 months for patients who did not receive maintenance therapy (n=98), received pemetrexed maintenance (n=58), or received maintenance therapy with pemetrexed plus Bev (n=54), respectively (HR=0.55; 95% CI, 0.40−0.76; P\<0.001) (*[Figure 2C](#Figure2){ref-type="fig"}*, *[Table 3](#Table3){ref-type="table"}*).

![Progression-free survival (PFS) curves between different groups of patients before and after propensity score-matching (PSM). (A) Patients who received pemetrexed-platinum-based chemotherapy (PPCT) with bevacizumab (Bev) had higher PFS than those who received chemotherapy without Bev before PSM (median PFS, 9.8 *vs*. 7.8 months; HR=0.722, 95% CI, 0.57−0.92, P=0.006); (B) Patients who received PPCT with Bev had higher PFS than those who received chemotherapy without Bev after PSM (median PFS, 9.8*vs*. 6.6 months; HR=0.56, 95% CI, 0.41−0.76, P\<0.001); (C) Patients receiving maintenance therapy with Bev plus pemetrexed (Pem) achieved superior PFS compared with those receiving non-maintenance treatment, or mono-Pem maintenance therapy (median PFS, 12.3*vs*. 4.8 *vs*. 8.6 months, HR=14.2, 95% CI, 9.27−13.19, P\<0.001). HR, hazard ratio; 95% CI, 95% confidence interval.](cjcr-31-5-749-2){#Figure2}

###### 

Baseline characteristics after propensity score-matched stratification by maintenance treatment

  Characteristics                                                                  Bev+Pem (n=54) \[n (%)\]   Pem (n=58) \[n (%)\]   None (n=98) \[n (%)\]   P
  -------------------------------------------------------------------------------- -------------------------- ---------------------- ----------------------- -------
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  　≥60 years                                                                      21 (38.9)                  19 (32.8)              42 (42.9)               0.458
  Male                                                                             24 (44.4)                  29 (50.0)              48 (49.0)               0.817
  ECOG PS                                                                                                                                                    0.086
  　0−1                                                                            53 (98.1)                  56 (96.6)              86 (87.8)               
  　≥2                                                                             1 (1.9)                    3 (5.2)                12 (12.2)               
  Smoking history                                                                  14 (25.9)                  20 (34.5)              33 (33.7)               0.454
  Comorbidities                                                                    28 (51.9)                  29 (50.0)              48 (49.0)               0.944
  Adenocarcinoma                                                                   53 (98.1)                  58 (100)               98 (100)                0.982
  EGFR positive                                                                    12 (22.2)                  9 (15.5)               32 (32.7)               0.292
  ALK positive                                                                     7 (13.0)                   1 (1.7)                9 (9.2)                 0.080
  Brain metastases                                                                 10 (18.5)                  5 (8.6)                12 (12.2)               0.286
  Pleural invasion                                                                 25 (46.3)                  24 (41.4)              36 (36.7)               0.510
  Weight loss \>5%                                                                 3 (5.6)                    1 (1.7)                9 (9.2)                 0.170
  History of hemoptysis                                                            4 (7.4)                    2 (3.4)                9 (9.2)                 0.404
  Previous surgery                                                                 11 (20.4)                  12 (20.7)              15 (15.3)               0.617
  Radiotherapy history                                                             13 (24.1)                  7 (12.1)               20 (20.4)               0.242

The relationship between the baseline characteristics of patients and PFS was explored via multivariate Cox analyses among patients before PSM (*[Figure 3](#Figure3){ref-type="fig"}*): a history of surgery and epidermal growth factor receptor (EGFR) mutation were also significant factors of prolonged PFS in patients with NS-NSCLC.

![Multivariate Cox analyses for progression-free survival (PFS) in 415 patients before propensity score-matching (PSM). ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; HR, hazard ratio; 95% CI, 95% confidence interval.](cjcr-31-5-749-3){#Figure3}

Safety profile {#s03.04}
--------------

The prevalence of Bev-associated serious adverse events (AEs), including hypertension, gastrointestinal perforations, arterial and venous thromboembolic events, hemoptysis, bleeding within the central nervous system, and other types of hemorrhage, were investigated. Consistent with the known profile of Bev at 7.5 mg/kg, the safety profile was acceptable in our study. Hemorrhagic events of grade ≥3 or new unexpected AEs in patients (including those with various complications) were not observed.

Discussion {#s04}
==========

Bev-containing chemotherapy has become standard first-line treatment for patients with advanced NS-NSCLC ([@b19]). Previous trials such as ECOG4599, AVAiL, SAiL, BEYOND and ARIES have demonstrated the superiority of Bev-containing chemotherapy with respect to ORR and PFS over chemotherapy alone against advanced NS-NSCLC (median PFS, 9.2−5.1*vs*. 6.5−4.5 months, P\<0.001) ([@b13],[@b19]-[@b23]). However, most of the chemotherapeutic regimens in those studies were paclitaxel/platinum, and the administration dose of Bev was 15 mg/kg. Interestingly, the AVAiL study showed that a lower dose (7.5 mg/kg) of Bev had comparable efficacy with a higher dose (15 mg/kg) in prolonging PFS ([@b21]). Most of the research data were generated from Western populations. The only Chinse study, BEYOUND, evaluated the efficacy of Bev at 15 mg/kg in combination with paclitaxel-platinum in a highly selective patient cohort, and showed a meaningful clinical benefit of Bev in Chinese patients with advanced NS-NSCLC ([@b23]).

However, three critical issues cannot be addressed by current research evidence. First, the optimal combination regimen (including the choice of maintenance treatment) has not been established ([@b24]-[@b27]). Second, the safety profile of Bev in patients with complications is not known. Third, the minimum effective and tolerable dose of Bev for Chinese population has not been determined. Therefore, we conducted a real-world study in Chinese patients with advanced NS-NSCLC to explore the efficacy of Bev-containing chemotherapy. Our results in 415 patients with NS-NSCLC further supported the notion that PFS can be improved significantly by employing a Bev-containing pemetrexed-platinum regimen. Bev administration was an independent beneficial prognostic factor for PFS (HR=1.51; P=0.036) in our study.

With regard to histology, gene mutation status and chemotherapy sensitivity, Chinese populations differ from those of Western people. The SAiL study showed a better ORR (68.8% *vs*. 50.8%), DCR (96.5% *vs*. 88.7%), median time to disease progression (TTP) (8.8 *vs*. 7.8 months) and overall survival (18.5 *vs*. 15.3 months) in 195 Chinese patients receiving first-line Bev combination therapy compared with the worldwide population ([@b28]). However, the survival benefits of the addition of Bev to chemotherapy have not been presented in older patients and those diagnosed with ECOG PS ≥2, brain metastases or comorbidities, even though such patients form a sizeable proportion of cancer sufferers ([@b29]). Although the ARIES study expanded the study of Bev into a broader real-world population ([@b30]), Asian populations were excluded.

Unlike ECOG4599 or AVAiL studies, our real-world study included assessment of older patients (age ≥60 years), pleural invasion, brain metastasis, ECOG PS ≥2, comorbidity medications and history of hemoptysis. With a median follow-up of 15.8 months, the median PFS was significantly different between Bev(+) and Bev(−) groups according to univariate analyses (9.8*vs*. 7.8 months, P=0.006). Among the 105 PSM-identified pairs, median PFS was significantly longer in Bev(+) patients (9.8 *vs*. 6.6 months, P\<0.001), suggesting a result that was consistent before and after PSM correction. Taken together, our study confirmed that a Bev-containing pemetrexed-platinum regimen was superior to the pemetrexed-platinum regimen in terms of PFS in a real-world Chinese population with NS-NSCLC.

As reported by the PARAMOUNT study, the choice of receiving pemetrexed maintenance after induction therapy with pemetrexed plus cisplatin is a vital factor for achieving better efficacy and reducing side effects for NS-NSCLC patients ([@b31]-[@b33]). Furthermore, the AVAPERL trial (MO22089) confirmed the survival benefits of Bev-containing pemetrexed maintenance therapy after first-line Bev-containing cisplatin-pemetrexed induction treatment in NS-NSCLC patients ([@b34]). Consistently, our study demonstrated that PFS was prolonged significantly with Bev-containing pemetrexed maintenance therapy than pemetrexed maintenance alone (7.4 *vs*. 3.7 months; HR=0.57; 95% CI, 0.44−0.75; P\<0.001) in overall and PSM-identified matched pairs (4.8*vs*. 8.6 *vs*. 12.3 months; HR=0.55; 95% CI, 0.40−0.76; P\<0.001). Therefore, Bev-containing pemetrexed maintenance treatment was an effective regimen in the NS-NSCLC patients who received Bev-containing pemetrexed-platinum induction therapy.

Importantly, patients in the present study received a low dose of Bev (7.5 mg/kg), which is in accordance with the healthcare policy and related financial concerns in China. With this low dose, which is half of the dose reported previously (15 mg/kg), the benefits of Bev in improving PFS combined with pemetrexed-platinum therapy followed by maintenance treatment were observed. Moreover, the lower dose of Bev employed in the present study achieved similar favorable survival outcomes compared with those of studies using a higher administration dose of Bev, though making direct comparisons is difficult ([@b20],[@b23],[@b34]). In addition, hypertension of grade I−II, proteinuria, venous thrombosis, and nosebleeds were the only AEs observed at this dose, suggesting that 7.5 mg/kg is a safe and efficacious dose.

Our study had several limitations: retrospective nature, small sample size, and undertaken at a single institution. These factors affected the statistical power of our data and could have resulted in biases. Though PSM was used to match pairs to minimize the potential selection bias, it compromised the sample size. Besides, the predictive value of the balanced variables in this study may be further explored in prospective settings.

Conclusions {#s05}
===========

This study provided essential clinical insights into a real-world Chinese cohort with advanced NS-NSCLC. First-line Bev-containing pemetrexed-platinum chemotherapy benefited prolongation of PFS considerably, especially among patients receiving Bev-containing maintenance treatment with pemetrexed. Importantly, 7.5 mg/kg of Bev was a low-dose, inexpensive and efficacious option in Chinese patients with advanced NS-NSCLC.
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